The efficacy and safety of palbociclib as first-line therapy in combination with letrozole in patients with advanced estrogen–receptor positive (ER+)/HER2– breast cancer was first demonstrated in the phase 2 PALOMA-1 study [10]. This evidence concerns the gene ERBB2 and breast cancer.